Erudio Healtherudio.com
Drug
Axicabtagene ciloleucel trials: what clinicians said in public
No HCP commentary report on a trial studying axicabtagene ciloleucel yet. Erudio has found public clinician commentary on 5 clinical trials studying axicabtagene ciloleucel, including ZUMA-1, ZUMA-12, ZUMA-22 and ZUMA-23. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| ZUMA-1 NCT02348216 · Kite, A Gilead Company DeepView → | refractory large B-cell lymphoma | Phase 1/Phase 2 | Deep | View | |||
| ZUMA-12 NCT03761056 · Kite, A Gilead Company DeepView → | first-line high-risk large B-cell lymphoma | Phase 2 | Deep | View | |||
| ZUMA-23 NCT05605899 · Kite, A Gilead Company DeepView → | first-line high-risk large B-cell lymphoma | Phase 3 | Deep | View | |||
| ZUMA-22 NCT05371093 · Kite, A Gilead Company DeepView → | relapsed/refractory follicular lymphoma | Phase 3 | Deep | View | |||
| ZUMA-7 NCT03391466 · Kite, A Gilead Company StandardView → | second-line relapsed/refractory diffuse large B-cell lymphoma | Phase 3 | Standard | View | |||